Call management and indicative planning for 2023-2024
Calls, evaluation and contracting in 2023
The Agency will oversee 17 calls under Horizon Europe Health in 2023-2024.
HaDEA will also contribute to delivering on the Commission’s Cancer Mission and Beating Cancer plan, with the implementation of one call for proposals in the area of cancer research in 2023.
In the first half of 2023, the Agency will concentrate its efforts on the preparation of grant agreements for up to 74 proposals shortlisted from the 4 of calls for proposals under the 2022 work programme.
HaDEA will also kick off the evaluation of 8 single-stage calls for proposals of the 2023 Cluster 1 Health Work Programme and 2023 Mission Cancer Work Programme, covering 32 topics for a total budget of €907.68 million. In addition, in late 2023, HaDEA will launch the 2024 single-stage calls and will evaluate one 2023 single-stage call and the 1st submissions of 2024 two-stage calls.
In parallel, the Agency will continue to implement and report on the legacy activities of Horizon 2020 Societal Challenge 1 (SC1) - Health, Demographic change and Wellbeing.
Tentative calendar 2023 – publication of open calls for proposals (grants)
Call identifier | Title of the action as per the 2023-2024 work programme of Horizon Europe Health | Indicative budget | Tentative publication date |
| Destination 3 - Tackling diseases and reducing disease burden |
| |
HORIZON-HLTH-2024-DISEASE-03-08-two-stage | Comparative effectiveness research for healthcare interventions in areas of high public health need | €45 000 000 | Q2 (26 April) |
HORIZON-HLTH-2024-DISEASE-03-11-two-stage | Pandemic preparedness and response: Adaptive platform trials for pandemic preparedness | €30 000 000 | Q2 (26 April) |
HORIZON-HLTH-2024-DISEASE-03-13-two-stage | Validation of fluid-derived biomarkers for the prediction and prevention of brain disorders | €25 000 000 | Q2 (26 April) |
HORIZON-HLTH-2024-DISEASE-03-14-two-stage
| Tackling under-researched high-burden medical conditions | €25 000 000 | Q2 (26 April) |
HORIZON-HLTH-2024-DISEASE-08-12
| Pandemic preparedness and response: Maintaining the European partnership for pandemic preparedness | €2 000 000 | Q3 (October) |
HORIZON-HLTH-2024-DISEASE-08-20
| Pandemic preparedness and response: Host-pathogen interactions of infectious diseases with epidemic potential | €50 000 000 | Q3 (October) |
HORIZON-HLTH-2024-DISEASE-09-01
| European Partnership: One Health Anti-Microbial Resistance | €100 000 000 | Q3 (October) |
| Destination 5 - Unlocking the full potential of new tools, technologies and digital solutions for a healthy society |
| |
HORIZON-HLTH-2024-TOOL-11-02
| Bio-printing of living cells for regenerative medicine | €25 000 000 | Q3 (October) |
| Destination 6 - Maintaining an innovative, sustainable and globally competitive health industry |
| |
HORIZON-HLTH-2024-IND-06-08
| Developing EU methodological frameworks for clinical/performance evaluation and post-market clinical/performance follow-up of medical devices and in vitro diagnostic medical devices (IVDs) | €10 000 000 | Q3 (October) |
HORIZON-HLTH-2024-IND-06-09
| Gaining experience and confidence in New Approach Methodologies (NAM) for regulatory safety and efficacy testing – coordinated training and experience | €2 000 000 | Q3 (October) |
Please note that the timing of publication is only indicative and might be subject to change.
Related links
Previous research programme Horizon 2020
Overview and priorities of Horizon 2020